NAMS logo

NAMS EBITDA

Annual EBITDA:

-$241.49M-$64.63M(-36.54%)
December 31, 2024

Summary

  • As of today, NAMS annual EBITDA is -$241.49 million, with the most recent change of -$64.63 million (-36.54%) on December 31, 2024.
  • During the last 3 years, NAMS annual EBITDA has fallen by -$200.12 million (-483.74%).
  • NAMS annual EBITDA is now -3533.17% below its all-time high of -$6.65 million, reached on December 1, 2020.

Performance

1-Year Change

-36.54%

3-Year Change

-483.74%

5-Year Change

-3533.17%

15-Year Change

-3533.17%

NAMS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

6.19%
NAMS annual EBITDA is higher than 6.19% of companies in Healthcare sector

Range

All-Time High

-$6.65M
NAMS annual EBITDA is currently -3533.17% below its historical high of -$6.65 million

3-Year Low

-$241.49M
NAMS annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NAMS previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NAMS next annual earnings announcement has not yet been scheduled

OtherNAMSincome statement metrics

Annual Revenue

$45.56M
NAMS annual revenue is $45.56 million

Annual Net Income

-$241.60M
NAMS annual net profit is -$241.60 million

Annual EBIT

-$241.60M
NAMS annual earnings before interest & taxes is -$241.60 million

Annual EPS

-$2.56
NAMS annual earnings per share is -$2.56

Quarterly EBITDA:

-$35.59M+$33.28M(+48.33%)
June 30, 2025

Summary

  • As of today, NAMS quarterly EBITDA is -$35.59 million, with the most recent change of +$33.28 million (+48.33%) on June 30, 2025.
  • Over the past year, NAMS quarterly EBITDA has increased by +$16.61 million (+31.81%).
  • NAMS quarterly EBITDA is now -27770.01% below its all-time high of -$127.70 thousand, reached on December 1, 2020.

Performance

3-Month Change

+48.33%

1-Year Change

+31.81%

3-Year Change

-1687.72%

5-Year Change

-27770.01%

NAMS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

13.19%
NAMS quarterly EBITDA is higher than 13.19% of companies in Healthcare sector

Range

All-Time High

-$127.70K
NAMS quarterly EBITDA is currently >-9900.00% below its historical high of -$127.70 thousand

3-Year Low

-$68.87M
NAMS quarterly EBITDA is currently +48.33% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2025
NAMS previous earnings announcement was published on Jun 30, 2025

Next Quarterly Earnings Report Date

Nov 5, 2025
NAMS next earnings announcement is scheduled for Nov 5, 2025

OtherNAMSincome statement metrics

Quarterly Revenue

$19.14M
NAMS quarterly revenue is $19.14 million

Quarterly Net Income

-$17.36M
NAMS quarterly net profit is -$17.36 million

Quarterly EBIT

-$35.63M
NAMS quarterly earnings before interest & taxes is -$35.63 million

Quarterly EPS

-$0.15
NAMS quarterly earnings per share is -$0.15

TTM EBITDA:

-$171.98M+$16.61M(+8.81%)
June 30, 2025

Summary

  • As of today, NAMS TTM EBITDA is -$171.98 million, with the most recent change of +$16.61 million (+8.81%) on June 30, 2025.
  • Over the past year, NAMS TTM EBITDA has dropped by -$64.84 million (-60.53%).
  • NAMS TTM EBITDA is now -134572.67% below its all-time high of -$127.70 thousand, reached on December 1, 2020.

Performance

3-Month Change

+8.81%

1-Year Change

-60.53%

3-Year Change

-5343.69%

5-Year Change

-134572.67%

NAMS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Percentile

9.27%
NAMS TTM EBITDA is higher than 9.27% of companies in Healthcare sector

Range

All-Time High

-$127.70K
NAMS TTM EBITDA is currently >-9900.00% below its historical high of -$127.70 thousand

3-Year Low

-$188.58M
NAMS TTM EBITDA is currently +8.81% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2025
NAMS previous earnings announcement was published on Jun 30, 2025

Next Quarterly Earnings Report Date

Nov 5, 2025
NAMS next earnings announcement is scheduled for Nov 5, 2025

OtherNAMSincome statement metrics

TTM Revenue

$64.01M
NAMS TTM revenue is $64.01 million

TTM Net Income

-$165.72M
NAMS TTM net profit is -$165.72 million

TTM EBIT

-$172.15M
NAMS TTM earnings before interest & taxes is -$172.15 million

TTM EPS

-$1.61
NAMS TTM earnings per share is -$1.61

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$241.49M
NAMS annual EBITDA is -$241.49 million

Annual Net Income

-$241.60M
NAMS annual net profit is -$241.60 million

Annual Interest Expense

$0.00
NAMS annual interest expense is $0.00

Annual Income Tax

-$1000.00
NAMS annual income tax is -$1000.00

Annual D&A

$113.00K
NAMS annual D&A is $113.00 thousand

NAMS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-36.5%+31.8%-60.5%
3Y3 Years-483.7%-1687.7%-5343.7%
5Y5 Years-3533.2%-10000.0%-10000.0%

NAMS EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-981.0%at low-1451.7%+48.3%-3283.0%+8.8%
5Y5-Year-3533.2%at low>-9999.0%+48.3%>-9999.0%+8.8%
All-TimeAll-Time-3533.2%at low>-9999.0%+48.3%>-9999.0%+8.8%

NAMS EBITDA History

DateAnnualQuarterlyTTM
Jun 2025
-
-$35.59M(+48.3%)
-$171.98M(+8.8%)
Mar 2025
-
-$68.87M(-59.5%)
-$188.58M(-8.0%)
Dec 2024
-$241.49M(-36.5%)
-$43.18M(-77.4%)
-$174.65M(-32.8%)
Sep 2024
-
-$24.34M(+53.4%)
-$131.47M(-22.7%)
Jun 2024
-
-$52.20M(+5.0%)
-$107.13M(-95.0%)
Mar 2024
-
-$54.94M(-54.7%)
-$54.94M(-38.0%)
Dec 2023
-$176.86M(-691.7%)
-
-
Mar 2023
-
-$35.51M
-$39.80M
DateAnnualQuarterlyTTM
Dec 2022
-$22.34M(+46.0%)
-
-
Sep 2022
-
-$2.29M(-15.2%)
-$5.08M(-60.9%)
Jun 2022
-
-$1.99M(-477.7%)
-$3.16M(-114.4%)
Mar 2022
-
-$344.60K(+24.2%)
-$1.47M(-7.9%)
Dec 2021
-$41.37M(-522.4%)
-$454.60K(-23.1%)
-$1.37M(-31.5%)
Sep 2021
-
-$369.20K(-21.0%)
-$1.04M(-55.1%)
Jun 2021
-
-$305.20K(-28.7%)
-$670.10K(-83.6%)
Mar 2021
-
-$237.20K(-85.7%)
-$364.90K(-185.7%)
Dec 2020
-$6.65M
-$127.70K
-$127.70K

FAQ

  • What is NewAmsterdam Pharma Company N.V. annual EBITDA?
  • What is the all-time high annual EBITDA for NewAmsterdam Pharma Company N.V.?
  • What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?
  • What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?
  • What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?
  • What is NewAmsterdam Pharma Company N.V. TTM EBITDA?
  • What is the all-time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?
  • What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?

What is NewAmsterdam Pharma Company N.V. annual EBITDA?

The current annual EBITDA of NAMS is -$241.49M

What is the all-time high annual EBITDA for NewAmsterdam Pharma Company N.V.?

NewAmsterdam Pharma Company N.V. all-time high annual EBITDA is -$6.65M

What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?

Over the past year, NAMS annual EBITDA has changed by -$64.63M (-36.54%)

What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?

The current quarterly EBITDA of NAMS is -$35.59M

What is the all-time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?

NewAmsterdam Pharma Company N.V. all-time high quarterly EBITDA is -$127.70K

What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?

Over the past year, NAMS quarterly EBITDA has changed by +$16.61M (+31.81%)

What is NewAmsterdam Pharma Company N.V. TTM EBITDA?

The current TTM EBITDA of NAMS is -$171.98M

What is the all-time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?

NewAmsterdam Pharma Company N.V. all-time high TTM EBITDA is -$127.70K

What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?

Over the past year, NAMS TTM EBITDA has changed by -$64.84M (-60.53%)
On this page